These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Two brothers with mild congenital erythropoietic porphyria due to a novel genotype. Berry AA; Desnick RJ; Astrin KH; Shabbeer J; Lucky AW; Lim HW Arch Dermatol; 2005 Dec; 141(12):1575-9. PubMed ID: 16365260 [TBL] [Abstract][Full Text] [Related]
4. C73R is a hotspot mutation in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. Frank J; Wang X; Lam HM; Aita VM; Jugert FK; Goerz G; Merk HF; Poh-Fitzpatrick MB; Christiano AM Ann Hum Genet; 1998 May; 62(Pt 3):225-30. PubMed ID: 9803266 [TBL] [Abstract][Full Text] [Related]
5. Congenital erythropoietic porphyria: identification and expression of exonic mutations in the uroporphyrinogen III synthase gene. Warner CA; Yoo HW; Roberts AG; Desnick RJ J Clin Invest; 1992 Feb; 89(2):693-700. PubMed ID: 1737856 [TBL] [Abstract][Full Text] [Related]
6. Congenital erythropoietic porphyria: mutation update and correlations between genotype and phenotype. Ged C; Moreau-Gaudry F; Richard E; Robert-Richard E; de Verneuil H Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):53-60. PubMed ID: 19268002 [TBL] [Abstract][Full Text] [Related]
7. Uroporphyrinogen III synthase knock-in mice have the human congenital erythropoietic porphyria phenotype, including the characteristic light-induced cutaneous lesions. Bishop DF; Johansson A; Phelps R; Shady AA; Ramirez MC; Yasuda M; Caro A; Desnick RJ Am J Hum Genet; 2006 Apr; 78(4):645-58. PubMed ID: 16532394 [TBL] [Abstract][Full Text] [Related]
12. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. To-Figueras J; Ducamp S; Clayton J; Badenas C; Delaby C; Ged C; Lyoumi S; Gouya L; de Verneuil H; Beaumont C; Ferreira GC; Deybach JC; Herrero C; Puy H Blood; 2011 Aug; 118(6):1443-51. PubMed ID: 21653323 [TBL] [Abstract][Full Text] [Related]
13. Uroporphyrinogen III synthase mutations related to congenital erythropoietic porphyria identify a key helix for protein stability. Fortian A; Castaño D; Ortega G; Laín A; Pons M; Millet O Biochemistry; 2009 Jan; 48(2):454-61. PubMed ID: 19099412 [TBL] [Abstract][Full Text] [Related]
14. Compound heterozygosity for a premature termination codon and missense mutation in the exon 10 of the uroporphyrinogen III cosynthase gene causes a severe phenotype of congenital erythropoietic porphyria. Kang TW; Oh SW; Kim MR; Lee JS; Kim SC J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):470-1. PubMed ID: 18647208 [No Abstract] [Full Text] [Related]
15. Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria. Blouin JM; Duchartre Y; Costet P; Lalanne M; Ged C; Lain A; Millet O; de Verneuil H; Richard E Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18238-43. PubMed ID: 24145442 [TBL] [Abstract][Full Text] [Related]
17. The prenatal presentation of congenital erythropoietic porphyria: report of two siblings with elevated maternal serum alpha-fetoprotein. Lazebnik N; Lazebnik RS Prenat Diagn; 2004 Apr; 24(4):282-6. PubMed ID: 15065102 [TBL] [Abstract][Full Text] [Related]
18. A systematic analysis of the mutations of the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. Fontanellas A; Bensidhoum M; Enriquez de Salamanca R; Moruno Tirado A; de Verneuil H; Ged C Eur J Hum Genet; 1996; 4(5):274-82. PubMed ID: 8946173 [TBL] [Abstract][Full Text] [Related]
19. A knock-in mouse model of congenital erythropoietic porphyria. Ged C; Mendez M; Robert E; Lalanne M; Lamrissi-Garcia I; Costet P; Daniel JY; Dubus P; Mazurier F; Moreau-Gaudry F; de Verneuil H Genomics; 2006 Jan; 87(1):84-92. PubMed ID: 16314073 [TBL] [Abstract][Full Text] [Related]